Zynerba Pharmaceuticals (NASDAQ:ZYNE) Rating Lowered to Buy at BidaskClub

Zynerba Pharmaceuticals (NASDAQ:ZYNE) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Wednesday, May 29th, BidAskClub reports.

Other research analysts have also issued research reports about the company. ValuEngine raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 17th. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $26.00 price target on shares of Zynerba Pharmaceuticals in a research report on Monday, May 6th. Zacks Investment Research lowered Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. Roth Capital assumed coverage on Zynerba Pharmaceuticals in a research report on Tuesday, April 30th. They set a “buy” rating and a $36.00 price target on the stock. Finally, Canaccord Genuity assumed coverage

... read more at: https://mayfieldrecorder.com/2019/06/07/zynerba-pharmaceuticals-zyne-rating-lowered-to-buy-at-bidaskclub.html

Leave a Reply